Met Prevent
MET-PREVENT
Metformin to prevent progression of sarcopenia and frailty in older people – a double blind, randomised controlled proof of concept trial
• Study stage: Closedown/Analysis
• Sponsor: The Newcastle upon Tyne Hospitals NHS Foundation Trust
• Funder: NIHR Newcastle Biomedical Research Centre
• Therapeutic area: Musculoskeletal
• Type of study: CTIMP
Aim: Provide proof-of-concept evidence as to whether metformin can improve physical performance in older people with sarcopenia and prefrailty
Primary Outcome: The between-group difference in 4m walk speed at 4 months, adjusted for baseline values.
• Population: Ageing
• Clinical Phase: IIII
• Design: Randomised Control Trial (RCT)
• Setting: Secondary Care
• Planned Sample Size: 80